Insider Monkey
FDA Accepts Achieve Life Sciences, Inc. (ACHV) NDA Application for Cytisinicline in Smoking Cessation
📊
AI Sentiment
Positive
7/10
- Home
- ACHV
as of 11-28-2025 12:39pm EST
$4.88
+$0.04
+0.83%
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
Chart Type:
Time Range:
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 167.6M | IPO Year: | N/A |
| Target Price: | $15.50 | AVG Volume (30 days): | 686.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.84 - $5.78 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered ACHV Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 70.21%
70.21%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Achieve Life Sciences Inc. (ACHV)
Stewart Richard Alistair
Sell
Chief Executive Officer
ACHV Sep 18, 2025
Avg Cost/Share
$2.92
Shares
129,501
Total Value
$378,142.92
Owned After
228,875
SEC Form 4
Oki Mark K
Sell
Chief Financial Officer
ACHV Sep 18, 2025
Avg Cost/Share
$2.92
Shares
50,060
Total Value
$146,175.20
Owned After
127,940
SEC Form 4
KING THOMAS BRAXTON
Sell
Director
ACHV Sep 4, 2025
Avg Cost/Share
$2.77
Shares
139,858
Total Value
$387,406.66
Owned After
315,142
SEC Form 4
JACOBS CINDY
Sell
President & CMO
ACHV Sep 4, 2025
Avg Cost/Share
$2.77
Shares
27,629
Total Value
$76,532.33
Owned After
115,585
SEC Form 4
Xinos Jaime
Sell
Chief Commercial Officer
ACHV Sep 4, 2025
Avg Cost/Share
$2.77
Shares
20,854
Total Value
$57,765.58
Owned After
74,432
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Stewart Richard Alistair | ACHV | Chief Executive Officer | Sep 18, 2025 | Sell | $2.92 | 129,501 | $378,142.92 | 228,875 | |
| Oki Mark K | ACHV | Chief Financial Officer | Sep 18, 2025 | Sell | $2.92 | 50,060 | $146,175.20 | 127,940 | |
| KING THOMAS BRAXTON | ACHV | Director | Sep 4, 2025 | Sell | $2.77 | 139,858 | $387,406.66 | 315,142 | |
| Wan Jerry | ACHV | Principal Accounting Officer | Sep 4, 2025 | Sell | $2.77 | 14,070 | $38,973.90 | 32,694 | |
| JACOBS CINDY | ACHV | President & CMO | Sep 4, 2025 | Sell | $2.77 | 27,629 | $76,532.33 | 115,585 | |
| Xinos Jaime | ACHV | Chief Commercial Officer | Sep 4, 2025 | Sell | $2.77 | 20,854 | $57,765.58 | 74,432 |
Latest Achieve Life Sciences Inc. News
ACHV Breaking Stock News: Dive into ACHV Ticker-Specific Updates for Smart Investing
Compare ACHV vs Leading Stocks
See how ACHV stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ACHV Achieve Life Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.